Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).
(NetworkNewsWire) With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. (NASDAQ:AZRX) core science team is the real strength behind the company's developing portfolio of recombinant therapies.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to announce the appointment of Lisa Dea as Chief Financial Officer of the Company effective immediately. Ms. Dea has also been appointed CFO of Harvest One Cannabis Inc. (CVE:HVST), and replaces Mr Kwong Choo, who will be assuming a new role as Vice President Finance of Harvest One.
Wilsons maintain a BUY rating and $1.66 price target. Anatara's recent stock underperformance has simply reflected a slow quarter for news in the lead-up to a significant inflection point in the 2H.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide investors with an update on recent progress.
It has come the attention of Queensland Bauxite Ltd (ASX:QBL) that there has been some confusion between Andrew Kavasilas of Medical Cannabis Limited and Andrew Katelaris. Andrew Katelaris, Dr Pot, allegedly caught last week with cash and cannabis, and consequently arrested, is NOT the Andrew Kavasilas of Medical Cannabis Limited.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to provide the following investor update presentation, the purpose of which is to provide shareholders with an update on the Company's activities and strategic outlook following the completion of the Harvest One Transaction last month.
